Oculis Holding AG (FRA:CR5) Moat Score: 3/10 (As of Jul. 30, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:CR5 Oculis Holding AG FRA:CR5
32 GF Score
Price €9.56
! 1 Warning Sign
View Full Analysis

What is Oculis Holding AG Moat Score?

Oculis Holding AG FRA:CR5 +5.29% 32 Moat Score is 3 as of Jul. 30, 2026. GuruFocus rates FRA:CR5 with a GF Score™ of 32/100. The stock has 1 warning sign investors should review. Among 1,394 Biotechnology companies, Oculis Holding AG ranks better than 75.61% on this metric.

Oculis Holding AG has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Oculis Holding AG has No Moat: Oculis Holding AG is in the early stages of development in the biotech sector with limited market leadership and no significant intellectual property or customer switching costs. Its competitive advantages are currently very weak.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Oculis Holding AG might have No Moat - Very weak/transient advantages.

Oculis Holding AG  (FRA:CR5) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Oculis Holding AG Moat Score Related Terms

FRA:CR5 vs RIGL, GYRE, SGP: Moat Score Comparison

For the Biotechnology subindustry, Oculis Holding AG's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oculis Holding AG Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oculis Holding AG's Moat Score distribution charts can be found below:

* The bar in red indicates where Oculis Holding AG's Moat Score falls into.


FRA:CR5
32GF Score
Oculis Holding AG FRA:CR5
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Oculis Holding AG (FRA:CR5) has a Moat Score of 3 as of Jul. 30, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Oculis Holding AG ranks #340 out of 1394 companies in the Biotechnology industry, placing it in the top 24.4%.
Is Oculis Holding AG's Moat Score too high?
Oculis Holding AG's current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. Oculis Holding AG's value of 3 is 50% above this industry median. Based on the distribution chart, Oculis Holding AG ranks #340 out of 1394 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Oculis Holding AG has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Oculis Holding AG's Moat Score compare to RIGL and GYRE?
According to the Biotechnology industry distribution chart, Oculis Holding AG ranks #340 out of 1394 companies for Moat Score. This places Oculis Holding AG in the top 24% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Oculis Holding AG's value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,394 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oculis Holding AG's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oculis Holding AG's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oculis Holding AG stock overvalued right now?
Oculis Holding AG (FRA:CR5) has a current Moat Score of 3. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. Oculis Holding AG's overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Oculis Holding AG (FRA:CR5), the current Moat Score is 3 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oculis Holding AG Business Description

Address Bahnhofstrasse 20, Zug, CHE, CH-6300
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.
32GF Score

Get the complete analysis for FRA:CR5

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.56
Price